2019 Cardio-Oncology Survey - FLASCO Membership

Question Title

* 1. How would you rate your knowledge of Cardio Oncology, cancer and heart disease ?

very high

some knowledge

neutral

little knowledge

no knowledge

Question Title

* 2. How comfortable are you treating patients with cancer therapy related cardiac toxicities?

very comfortable

somewhat comfortable

neutral

uncomfortable

Question Title

* 3. What is your most common approach to cardiovascular events, complications, or treatment of cardiovascular risk factors in patients with cancer prior or during their treatment/chemotherapy?

consult to internist

general cardiologist

cardio-oncologist

refer them out of town due to lack of local resources

Question Title

* 4. What are the 3 most common cardiovascular toxic effects you have seen in your service? Please name the relevant cancer therapy medication for each. (i.e. decline in LVEF/heart failure, myocardial ischemia, pericarditis, myocarditis, valvular heart disease, arrhythmia, venous or arterial thromboembolic events, pulmonary hypertension, QT prolongation)

Question Title

* 5. How often/commonly do your patients face potential cardiotoxicity caused by cancer therapies in your service?

Very often-every day

Common-more than once per week

Not often - less than once per week

More than once per month

Rarely-less than once per month

Question Title

* 6. Are there dedicated cardio oncology services in your hospital/community?

yes

I don’t know

If yes, have you referred any patients to those services?

Question Title

* 7. What level of cooperation do you have with your local cardiologists for co-management of cardiovascular complications of cancer treatment?

excellent

some cooperation

neutral

little cooperation

no cooperation

Question Title

* 8. Are there local cardio oncology educational resources in your community? (i.e. conferences or tumor boards with cardiology input case presentation meetings)

yes

Question Title

* 9. Would you find these resources of value?

yes

Question Title

* 10. What are the main barriers in establishing a cardio oncology program/practice in your community: (check all that apply)

lack of awareness

lack of mentoring

lack of interest

lack of financial resources

inadequate reimbursement

not considered important

political/employer referral bias

Question Title

* 11. How many educational programs or sessions in Cardio Oncology or Cardiovascular complications of cancer treatment have you attended in the last 3-5 years?

none

2-3

Question Title

* 12. Are there any important issues concerning Cancer and Cardio-vascular diseases in your community that need be addressed?

Question Title

* 13. Please provide the following demographics: age, gender, type of practice (private/academic/hospital employed/single vs specialty group)

Question Title

* 14. Are you familiar with the cardiotoxicity of the following cancer therapies?

	Yes	NO
Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone	Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone Yes	Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone NO
Platinum : cisplatin, carboplantin, oxaliplatin	Platinum : cisplatin, carboplantin, oxaliplatin Yes	Platinum : cisplatin, carboplantin, oxaliplatin NO
Antimetabolites: Fluorouracil, Capecitabine	Antimetabolites: Fluorouracil, Capecitabine Yes	Antimetabolites: Fluorouracil, Capecitabine NO
Alkylating agents : Cyclophosphamide	Alkylating agents : Cyclophosphamide Yes	Alkylating agents : Cyclophosphamide NO
Antimicrotubule agent : Paclitaxel	Antimicrotubule agent : Paclitaxel Yes	Antimicrotubule agent : Paclitaxel NO
HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib	HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib Yes	HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib NO
VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib	VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib Yes	VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib NO
Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib	Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib Yes	Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib NO
Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib	Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib Yes	Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib NO
Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide	Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide Yes	Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide NO
Proteasome inhibitors: bortezomib, carfilzomib	Proteasome inhibitors: bortezomib, carfilzomib Yes	Proteasome inhibitors: bortezomib, carfilzomib NO
Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab	Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab Yes	Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab NO

Question Title

* 15. Which of the following medications will motivate you to perform a formal cardiac evaluation?

	Yes	NO
Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone	Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone Yes	Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone NO
Platinum : cisplatin, carboplantin, oxaliplatin	Platinum : cisplatin, carboplantin, oxaliplatin Yes	Platinum : cisplatin, carboplantin, oxaliplatin NO
Antimetabolites: Fluorouracil, Capecitabine	Antimetabolites: Fluorouracil, Capecitabine Yes	Antimetabolites: Fluorouracil, Capecitabine NO
Alkylating agents : Cyclophosphamide	Alkylating agents : Cyclophosphamide Yes	Alkylating agents : Cyclophosphamide NO
Antimicrotubule agent : Paclitaxel	Antimicrotubule agent : Paclitaxel Yes	Antimicrotubule agent : Paclitaxel NO
HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib	HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib Yes	HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib NO
VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib	VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib Yes	VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib NO
Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib	Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib Yes	Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib NO
Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib	Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib Yes	Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib NO
Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide	Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide Yes	Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide NO
Proteasome inhibitors: bortezomib, carfilzomib	Proteasome inhibitors: bortezomib, carfilzomib Yes	Proteasome inhibitors: bortezomib, carfilzomib NO
Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab	Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab Yes	Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab NO

Question Title

* 16. Which of the following cancer therapies have you seen, in your practice, cause cardio toxicity?

	Yes	NO
Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone	Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone Yes	Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone NO
Platinum : cisplatin, carboplantin, oxaliplatin	Platinum : cisplatin, carboplantin, oxaliplatin Yes	Platinum : cisplatin, carboplantin, oxaliplatin NO
Antimetabolites: Fluorouracil, Capecitabine	Antimetabolites: Fluorouracil, Capecitabine Yes	Antimetabolites: Fluorouracil, Capecitabine NO
Alkylating agents : Cyclophosphamide	Alkylating agents : Cyclophosphamide Yes	Alkylating agents : Cyclophosphamide NO
Antimicrotubule agent : Paclitaxel	Antimicrotubule agent : Paclitaxel Yes	Antimicrotubule agent : Paclitaxel NO
HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib	HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib Yes	HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib NO
VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib	VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib Yes	VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib NO
Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib	Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib Yes	Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib NO
Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib	Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib Yes	Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib NO
Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide	Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide Yes	Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide NO
Proteasome inhibitors: bortezomib, carfilzomib	Proteasome inhibitors: bortezomib, carfilzomib Yes	Proteasome inhibitors: bortezomib, carfilzomib NO
Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab	Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab Yes	Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab NO